Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome

Lucas L. Van Den Hoogen, Joël A.G. Van Roon, Jorre S. Mertens, Judith Wienke, Ana Pinheiro Lopes, Wilco De Jager, Marzia Rossato, Aridaman Pandit, Catharina G.K. Wichers, Femke Van Wijk, Ruth D.E. Fritsch-Stork, Timothy R.D.J. Radstake

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

43 Citaten (Scopus)

Samenvatting

Objective The interferon (IFN) signature is related to disease activity and vascular disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and represents a promising therapeutic target. Quantification of the IFN signature is currently performed by gene expression analysis, limiting its current applicability in clinical practice. Therefore, the objective of this study was to establish an easy to measure biomarker for the IFN signature. Methods Serum levels of galectin-9, CXCL-10 (IP-10) and tumour necrosis factor receptor type II (TNF-RII) were measured in patients with SLE, SLE+APS and primary APS (PAPS) and healthy controls (n=148) after an initial screening of serum analytes in a smaller cohort (n=43). Analytes were correlated to measures of disease activity and the IFN signature. The performance of galectin-9, CXCL-10 and TNF-RII as biomarkers to detect the IFN signature was assessed by receiver operating characteristic curves. Results Galectin-9, CXCL-10 and TNF-RII were elevated in patients with SLE, SLE+APS and PAPS (p<0.05) and correlated with disease activity and tissue factor expression. Galectin-9 correlated stronger than CXCL-10 or TNF-RII with the IFN score (r=0.70, p<0.001) and was superior to CXCL-10 or TNF-RII in detecting the IFN signature (area under the curve (AUC) 0.86). Importantly, in patients with SLE(±APS), galectin-9 was also superior to anti-dsDNA antibody (AUC 0.70), or complement C3 (AUC 0.70) and C4 (AUC 0.78) levels in detecting the IFN signature. Conclusion Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the IFN signature in patients with systemic autoimmune diseases such as SLE and APS.

Originele taal-2Engels
Pagina's (van-tot)1810-1814
Aantal pagina's5
TijdschriftAnnals of the Rheumatic Diseases
Volume77
Nummer van het tijdschrift12
DOI's
StatusGepubliceerd - 1 dec. 2018
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome'. Samen vormen ze een unieke vingerafdruk.

Citeer dit